{"product_id":"tars-vrio-analysis","title":"Tarsus Pharmaceuticals, Inc. (TARS): VRIO Analysis [Mar-2026 Updated]","description":"\u003cbr\u003e\u003cp\u003eUnlock the secrets to Tarsus Pharmaceuticals, Inc. (TARS)'s market strength with this sharp VRIO Analysis. We distill whether its current assets truly translate into a sustainable competitive advantage by rigorously testing their Value, Rarity, Inimitability, and organizational alignment. Dive in now to see the definitive assessment of Tarsus Pharmaceuticals, Inc. (TARS)'s core capabilities and what truly sets it apart from the competition.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eTarsus Pharmaceuticals, Inc. (TARS) - VRIO Analysis: 1. XDEMVY Commercial Momentum and Market Position\n\u003c\/h2\u003e\n\u003cp\u003eYou’re looking at the commercial engine driving Tarsus Pharmaceuticals, Inc. right now, and frankly, it’s firing on all cylinders. XDEMVY is not just a product; it’s a category creator in Demodex blepharitis, and the Q3 2025 numbers back that up emphatically. We need to assess this asset through the VRIO lens to see how long that lead will last.\u003c\/p\u003e\n\u003cp\u003eThe immediate value is clear: XDEMVY generated net sales of $118.7 million in the third quarter of 2025, with the company shipping over 103,000 bottles to patients that quarter alone. That’s serious top-line momentum. The market is validating the need, which is why Tarsus has successfully scaled its reach to more than 20,000 prescribing Eye Care Professionals (ECPs). That’s a significant footprint for a relatively new launch. What this estimate hides is the pressure on margins; the gross-to-net discount for the quarter settled at 44.7%, which you need to factor into your forward-looking revenue assumptions.\u003c\/p\u003e\n\u003cp\u003eHere’s the quick math on the competitive standing based on the VRIO framework for this asset:\u003c\/p\u003e\n\u003ctable\u003e\n  \u003ctr\u003e\n    \u003ctd\u003e\u003cstrong\u003eVRIO Dimension\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003eAssessment\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003eKey Supporting Data (2025 Fiscal)\u003c\/strong\u003e\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eValue\u003c\/td\u003e\n    \u003ctd\u003eHigh\u003c\/td\u003e\n    \u003ctd\u003eQ3 2025 Net Sales: \u003cstrong\u003e$118.7 million\u003c\/strong\u003e\n\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eRarity\u003c\/td\u003e\n    \u003ctd\u003eHigh\u003c\/td\u003e\n    \u003ctd\u003eFirst and only FDA-approved therapeutic for Demodex blepharitis.\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eInimitability\u003c\/td\u003e\n    \u003ctd\u003eMedium-Low\u003c\/td\u003e\n    \u003ctd\u003eRegulatory moat exists, but market validation attracts fast followers.\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eOrganization\u003c\/td\u003e\n    \u003ctd\u003eHigh\u003c\/td\u003e\n    \u003ctd\u003eOver \u003cstrong\u003e20,000\u003c\/strong\u003e ECPs prescribing; 30% Q\/Q growth in high-volume prescribers.\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eCompetitive Advantage\u003c\/td\u003e\n    \u003ctd\u003eTemporary\u003c\/td\u003e\n    \u003ctd\u003eStrong current position, but first-mover advantage erodes over time.\u003c\/td\u003e\n  \u003c\/tr\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe rarity factor is Tarsus’s biggest shield right now. XDEMVY is the first and only FDA-approved therapeutic for this condition, which means competitors can’t just copy the formula; they have to go through the entire regulatory gauntlet again. Still, this success validates the market, and that’s a magnet for capital and R\u0026amp;D dollars from bigger players looking to enter the space. That’s why I peg imitability as medium-low, not impossible.\u003c\/p\u003e\n\u003cp\u003eThe organization around this asset is currently high, which is crucial for realizing its potential. Tarsus has demonstrated it can execute the commercial plan. Consider these adoption metrics:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eReached over \u003cstrong\u003e20,000\u003c\/strong\u003e ECPs prescribing.\u003c\/li\u003e\n\u003cli\u003eECPs writing \u0026gt;1 bottle\/week grew \u003cstrong\u003e30%\u003c\/strong\u003e in Q3 2025.\u003c\/li\u003e\n\u003cli\u003eReimbursement coverage extends to over \u003cstrong\u003e90%\u003c\/strong\u003e of commercial, Medicare, and Medicaid lives.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThis strong execution solidifies a temporary competitive advantage. If onboarding new prescribers slows down or a competitor launches a near-equivalent product by late 2026, that advantage will definitely shrink. Finance: draft 13-week cash view by Friday.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eTarsus Pharmaceuticals, Inc. (TARS) - VRIO Analysis: 2. Lotilaner Molecule Platform\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e The active ingredient, lotilaner, is a highly lipophilic agent that paralyzes and eradicates mites by inhibiting parasite-specific GABA-Cl channels, underpinning the entire pipeline. Lotilaner kills parasites by inhibiting their GABA chloride channel, which paralyzes the parasite and then kills it in under \u003cstrong\u003e24 hours\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e High; this specific mechanism of action for these indications is unique to Tarsus's assets. XDEMVY ($\\text{lotilaner ophthalmic solution, 0.25\\%}$) is the only FDA-approved medicine for the treatment of Demodex blepharitis.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Low for the molecule itself, as it is licensed, but the application across multiple indications is hard to replicate quickly. Tarsus is advancing the pipeline based on this single molecule.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High; the company is organized to leverage this single molecule across eye care and infectious disease. Research and development (R\u0026amp;D) expenses for Q2 2025 were \u003cstrong\u003e$15.6 million\u003c\/strong\u003e, which included \u003cstrong\u003e$0.8 million\u003c\/strong\u003e of increased TP-04 program expenses. R\u0026amp;D expenses for Q3 2025 were \u003cstrong\u003e$16.3 million\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary; sustained only as long as the underlying licensing agreements provide exclusivity for these uses. Patent exclusivity for TP-04 is expected to extend through \u003cstrong\u003e2038\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003eThe application of lotilaner across the pipeline is detailed below:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eIndication\/Product\u003c\/td\u003e\n\u003ctd\u003eStatus\/Formulation\u003c\/td\u003e\n\u003ctd\u003eKey Metric\/Data Point\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDemodex Blepharitis (XDEMVY)\u003c\/td\u003e\n\u003ctd\u003eFDA Approved (Ophthalmic Solution 0.25%)\u003c\/td\u003e\n\u003ctd\u003eQ2 2025 Net Sales: \u003cstrong\u003e$118.7 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOcular Rosacea (TP-04)\u003c\/td\u003e\n\u003ctd\u003ePhase 2 (Gel)\u003c\/td\u003e\n\u003ctd\u003ePhase 2 study initiation planned for December 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLyme Disease Prevention (TP-05)\u003c\/td\u003e\n\u003ctd\u003ePhase 2 (Oral Tablet)\u003c\/td\u003e\n\u003ctd\u003ePhase 2 study planned to initiate in 2026\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMalaria\u003c\/td\u003e\n\u003ctd\u003ePhase 1 Studies\u003c\/td\u003e\n\u003ctd\u003eTP-05 formulation moving into Phase 1 studies\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eCommercial performance metrics for XDEMVY include:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eQ2 2025 net sales reached \u003cstrong\u003eover $100 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eQ1 2025 product sales were \u003cstrong\u003e$78.3 million\u003c\/strong\u003e, representing a \u003cstrong\u003e217%\u003c\/strong\u003e year-over-year increase.\u003c\/li\u003e\n\u003cli\u003eMore than \u003cstrong\u003e103,000\u003c\/strong\u003e bottles of XDEMVY were delivered to patients in Q3 2025.\u003c\/li\u003e\n\u003cli\u003eMore than \u003cstrong\u003e20,000\u003c\/strong\u003e Eye Care Professionals (ECPs) were prescribing XDEMVY as of Q2 2025.\u003c\/li\u003e\n\u003cli\u003eGross-to-net discount percentage for XDEMVY was in the \u003cstrong\u003elow 40s\u003c\/strong\u003e as of the end of Q3 2024.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eLicensing and exclusivity details:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eLotilaner was exclusively licensed to Tarsus from Elanco in \u003cstrong\u003e2019\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe agreement for U.S. net sales royalties for XDEMVY applies from \u003cstrong\u003eApril 2025 through August 2033\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eElanco sold certain future tiered royalties and commercial milestones for \u003cstrong\u003e$295 million\u003c\/strong\u003e in cash.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eTarsus Pharmaceuticals, Inc. (TARS) - VRIO Analysis: 3. TP-04 Ocular Rosacea Pipeline Asset\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Addresses Ocular Rosacea (OR), a highly prevalent condition with no FDA-approved therapy, with a Phase 2 study starting in the \u003cstrong\u003esecond half of 2025\u003c\/strong\u003e. Approximately \u003cstrong\u003e15-18 million people in the United States\u003c\/strong\u003e are affected by Ocular Rosacea.\u003c\/p\u003e\n\n\u003cp\u003eThe unmet need is situated within the broader Rosacea Treatment Market, which was valued at \u003cstrong\u003eUSD 2.27 billion in 2025\u003c\/strong\u003e globally and is projected to reach \u003cstrong\u003eUSD 3.46 billion by 2030\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\/Range\u003c\/th\u003e\n\u003cth\u003eSource Year\/Period\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eUS Ocular Rosacea Prevalence\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e15-18 million\u003c\/strong\u003e Americans affected\u003c\/td\u003e\n\u003ctd\u003eCurrent\/Recent Data\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFDA-Approved OR Therapies\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eZero\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eCurrent Data\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGlobal Rosacea Treatment Market Size\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eUSD 2.27 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e2025 Estimate\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGlobal Rosacea Treatment Market Projection\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eUSD 3.46 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e2030 Estimate\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Medium; other firms target OR, but TP-04 has a clear, late-stage development path, with a Phase 2 study planned to initiate in the \u003cstrong\u003esecond half of 2025\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Low; requires successful clinical trial execution and regulatory navigation. Patent exclusivity for TP-04 is expected to extend through \u003cstrong\u003e2038\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High; the company has a clear, near-term clinical catalyst planned for \u003cstrong\u003elate 2025\u003c\/strong\u003e. Tarsus Pharmaceuticals reported trailing 12-month revenue of \u003cstrong\u003e$366M\u003c\/strong\u003e as of September 30, 2025, and a market capitalization of \u003cstrong\u003e$2.85B\u003c\/strong\u003e as of October 29, 2025.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary; advantage is based on being first-to-market if successful, but this is not yet proven.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003eTP-04 is an investigational ophthalmic gel formulation of lotilaner.\u003c\/li\u003e\n\u003cli\u003eLotilaner is a well-characterized antiparasitic agent that paralyzes and kills \u003cem\u003eDemodex\u003c\/em\u003e mites.\u003c\/li\u003e\n\u003cli\u003ePrevious clinical trials of lotilaner in Demodex blepharitis generated \u003cstrong\u003e$180.1 million\u003c\/strong\u003e in net product sales for full-year 2024 for XDEMVY.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eTarsus Pharmaceuticals, Inc. (TARS) - VRIO Analysis: 4. TP-05 Lyme Disease Prevention Program\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Represents a novel, non-vaccine, on-demand oral tablet designed to prevent Lyme disease transmission by killing ticks. The potential market addresses an estimated $1 billion price tag for the US healthcare system associated with Lyme disease, with up to 476,000 potential annual diagnoses in the U.S.. TP-05 is in Phase 2 clinical studies.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e High; a unique prophylactic approach in the infectious disease prevention space, as TP-05 is believed to be the only non-vaccine, drug-based, preventative therapeutic in development designed to kill ticks to potentially prevent Lyme disease transmission. There are currently no FDA-approved pharmacological prophylactic options for Lyme disease.\u003c\/p\u003e\n\n\u003cp\u003eThe Phase 2a Carpo trial demonstrated significant tick mortality:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eHigh Dose Mean Tick Mortality (24h post-challenge)\u003c\/th\u003e\n\u003cth\u003eLow Dose Mean Tick Mortality (24h post-challenge)\u003c\/th\u003e\n\u003cth\u003ePlacebo Mean Tick Mortality (24h post-challenge)\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDay 1 Challenge\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e97.0%\u003c\/strong\u003e (± 1.4 SE)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e92.0%\u003c\/strong\u003e (± 6.3 SE)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e5.0%\u003c\/strong\u003e (± 2.5 SE)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDay 30 Challenge\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e89.0%\u003c\/strong\u003e (± 11.1 SE)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e91.0%\u003c\/strong\u003e (± 6.1 SE)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e9.0%\u003c\/strong\u003e (± 8.0 SE)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eKilling ticks within 24 hours of attachment is critical, as transmission typically requires 36-48 hours or more.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Low; requires significant, specialized development and regulatory pathway navigation. The active ingredient, lotilaner, has an extended half-life potentially supporting a monthly or less frequent therapy regimen.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High; the pipeline is structured to pursue category creation in infectious disease. Financial commitment is evidenced by Research and development (R\u0026amp;D) expenses for Q3 2024 being $36.5 million, with $2.2 million less program spend allocated to TP-05 compared to the same period in 2023. R\u0026amp;D non-cash stock compensation expense for Q3 2024 was $5.0 million.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained; if successful, it creates an entirely new prevention category, offering a durable advantage. The potential for rapid and durable protection against multiple tick-borne diseases is noted.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eTP-05 is an oral systemic formulation of lotilaner.\u003c\/li\u003e\n\u003cli\u003eLotilaner kills parasites by inhibiting their GABA chloride channel, paralyzing and killing them in under 24 hours.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eTarsus Pharmaceuticals, Inc. (TARS) - VRIO Analysis: 5. XDEMVY Broad Payer Access\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Secures market adoption by covering more than \u003cstrong\u003e90%\u003c\/strong\u003e of commercial, Medicare, and Medicaid lives. This access underpins realized revenue, such as the \u003cstrong\u003e$118.7 million\u003c\/strong\u003e in net product sales reported for Q3 2025. The realized revenue is subject to the gross-to-net discount, which was reported at \u003cstrong\u003e44.7%\u003c\/strong\u003e for Q3 2025.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Medium-high; achieving this breadth of coverage for a new product is a significant hurdle cleared, evidenced by the \u003cstrong\u003e90%\u003c\/strong\u003e coverage across major US payer segments.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Medium; payer negotiations are complex but follow industry patterns. The gross-to-net discount rate reflects the outcome of these negotiations, with figures reported as low as the \u003cstrong\u003elow 40s%\u003c\/strong\u003e in Q3 2024 and as high as \u003cstrong\u003e47%\u003c\/strong\u003e in Q1 2025.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High; the commercial team successfully navigated complex US market access requirements, leading to strong adoption metrics.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained; formulary inclusion creates a sticky barrier to entry for future competitors.\u003c\/p\u003e\n\u003cp\u003eKey metrics demonstrating the impact of broad payer access and subsequent commercial execution:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eData Point\u003c\/td\u003e\n\u003ctd\u003eReporting Period\/Context\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePayer Coverage (Commercial, Medicare, Medicaid)\u003c\/td\u003e\n\u003ctd\u003eMore than \u003cstrong\u003e90%\u003c\/strong\u003e of lives\u003c\/td\u003e\n\u003ctd\u003eAs of Q3 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross-to-Net Discount\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e44.7%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ3 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Product Sales\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$118.7 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ3 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBottles Delivered to Patients\u003c\/td\u003e\n\u003ctd\u003eMore than \u003cstrong\u003e103,000\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eQ3 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eECPs Writing Multiple Prescriptions (YoY Growth)\u003c\/td\u003e\n\u003ctd\u003eIncreased by approximately \u003cstrong\u003e30%\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eQ3 2025 vs Q2 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eFurther evidence of organizational success in leveraging payer access:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eMore than \u003cstrong\u003e20,000\u003c\/strong\u003e Eye Care Professionals (ECPs) have written multiple prescriptions as of Q3 2025.\u003c\/li\u003e\n\u003cli\u003eIn Q1 2025, the number of ECPs writing more than one prescription per week increased by nearly \u003cstrong\u003e110%\u003c\/strong\u003e compared to Q3 2024.\u003c\/li\u003e\n\u003cli\u003eTotal XDEMVY net product sales for the full year 2024 reached \u003cstrong\u003e$180.1 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eTarsus Pharmaceuticals, Inc. (TARS) - VRIO Analysis: 6. Commercial Execution and Category Creation Strategy\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e The ability to create and define a new treatment category (Demodex blepharitis) and drive adoption through targeted marketing.\u003c\/p\u003e\n\u003cp\u003eXDEMVY is the \u003cstrong\u003efirst and only\u003c\/strong\u003e FDA-approved treatment for Demodex blepharitis (DB), a condition Tarsus reckons may impact as many as \u003cstrong\u003e25 million Americans\u003c\/strong\u003e. The commercial execution has resulted in rapid sales acceleration:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eQ1 2025\u003c\/th\u003e\n\u003cth\u003eQ2 2025\u003c\/th\u003e\n\u003cth\u003eQ3 2025\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Product Sales\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$78.3 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$102.7 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$118.7 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBottles Dispensed to Patients\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e72,000\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e91,000\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eMore than \u003cstrong\u003e103,000\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e High; few companies successfully create and dominate a new category from scratch.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eXDEMVY is the \u003cstrong\u003efirst and only\u003c\/strong\u003e FDA-approved treatment for Demodex blepharitis.\u003c\/li\u003e\n\u003cli\u003eMore than \u003cstrong\u003e20,000 ECPs\u003c\/strong\u003e are now prescribing XDEMVY.\u003c\/li\u003e\n\u003cli\u003eReimbursement coverage secured for over \u003cstrong\u003e90% of U.S. patients\u003c\/strong\u003e across commercial, Medicare, and Medicaid lives.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Medium-low; requires a specific blend of scientific insight, marketing spend, and ECP engagement.\u003c\/p\u003e\n\u003cp\u003eThe investment in commercial infrastructure and awareness campaigns contributes to inimitability:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eSelling, General \u0026amp; Administrative (SG\u0026amp;A) expenses in 2024 included \u003cstrong\u003e$52.0 million\u003c\/strong\u003e of increased commercial and marketing costs related to the XDEMVY launch.\u003c\/li\u003e\n\u003cli\u003eConsumer unaided awareness of XDEMVY has more than \u003cstrong\u003etripled\u003c\/strong\u003e since the Direct-To-Consumer (DTC) campaign began.\u003c\/li\u003e\n\u003cli\u003eActive consumer engagement on XDEMVY.com website is up nearly \u003cstrong\u003e400%\u003c\/strong\u003e since the beginning of 2025.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High; the entire corporate structure appears aligned around this category-creation blueprint.\u003c\/p\u003e\n\u003cp\u003eOrganizational alignment is evidenced by scaling commercial reach and pipeline development:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eTarsus was on track to deploy an additional \u003cstrong\u003e50 sales representatives\u003c\/strong\u003e by the end of Q3 2024.\u003c\/li\u003e\n\u003cli\u003eThe company is leveraging XDEMVY's traction to fund pipeline advancement, with plans to engage the FDA on investigational therapies TP-03, TP-04, and TP-05 by the end of 2024.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained; the strategic framework itself, if consistently applied, is a source of advantage.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eTarsus Pharmaceuticals, Inc. (TARS) - VRIO Analysis: 7. Strong Balance Sheet Liquidity\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Cash, cash equivalents, and marketable securities totaled \u003cstrong\u003e$401.8 million\u003c\/strong\u003e as of September 30, 2025, funding operations and pipeline advancement.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Medium; this level of cash provides significant operational runway in the sector, especially when supported by accelerating product sales.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Low; requires successful equity\/debt financing or strong product sales to build.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High; management is using this capital to fund ongoing commercial expansion and pipeline development.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary; cash reserves are finite and must be replenished through sales or future financing.\u003c\/p\u003e\n\u003cp\u003eThe strong liquidity position is underpinned by significant product revenue growth:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eNet product sales for the quarter ended September 30, 2025, were \u003cstrong\u003e$118.7 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eYear-to-date product sales for 2025 reached \u003cstrong\u003e$299.7 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe number of bottles of XDEMVY delivered to patients in Q3 2025 was more than \u003cstrong\u003e103,000\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe gross-to-net discount for XDEMVY in Q3 2025 was \u003cstrong\u003e44.7%\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe company reported a net loss of \u003cstrong\u003e$12.6 million\u003c\/strong\u003e for the quarter ended September 30, 2025.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThe following table details key financial metrics as of the latest reported period:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue as of September 30, 2025\u003c\/th\u003e\n\u003cth\u003eComparison to September 30, 2024\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash, Cash Equivalents, and Marketable Securities\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$401.8 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eUp from $317.0 million\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ3 Net Product Sales (XDEMVY)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$118.7 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eUp approximately 147% year-over-year from $48.1 million\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eYTD Net Product Sales (2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$299.7 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eUp from $113.7 million for the same period in 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ3 Net Loss\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$12.6 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eImproved from a net loss of $23.4 million\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ3 Basic and Diluted Net Loss Per Share\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$(0.30)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eImproved from $(0.61)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eManagement's utilization of this capital is focused on commercial momentum and pipeline progression:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eMore than \u003cstrong\u003e90%\u003c\/strong\u003e of commercial, Medicare, and Medicaid lives have XDEMVY coverage.\u003c\/li\u003e\n\u003cli\u003eThe number of eye care professionals (ECPs) prescribing more than one bottle per week increased by approximately \u003cstrong\u003e30%\u003c\/strong\u003e in Q3 2025 compared to Q2 2025.\u003c\/li\u003e\n\u003cli\u003eTotal SG\u0026amp;A non-cash stock compensation expense for Q3 2025 was \u003cstrong\u003e$9.1 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eTarsus Pharmaceuticals, Inc. (TARS) - VRIO Analysis: 8. Established US Regulatory and Commercial Infrastructure\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Possessing the necessary infrastructure, experience, and relationships to bring a novel ophthalmic product through FDA approval and into the US market.\u003c\/p\u003e\n\n\u003cp\u003eThe value is evidenced by the successful navigation of the regulatory pathway, culminating in the U.S. Food and Drug Administration (FDA) approval for XDEMVY in July \u003cstrong\u003e2023\u003c\/strong\u003e, followed by a commercial launch in August \u003cstrong\u003e2023\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003eThe established commercial infrastructure is actively driving adoption, as demonstrated by key performance indicators:\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eData Point\u003c\/th\u003e\n\u003cth\u003eReporting Period\/Date\u003c\/th\u003e\n\u003cth\u003eCitation\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eXDEMVY Net Product Sales\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$78.3 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ1 2025\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eXDEMVY Bottles Dispensed\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e72,000\u003c\/strong\u003e bottles\u003c\/td\u003e\n\u003ctd\u003eQ1 2025\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal ECPs Starting Patients\u003c\/td\u003e\n\u003ctd\u003eMore than \u003cstrong\u003e13,000\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eAs of November 13, 2024\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eECPs Writing \u0026gt;1 Rx\/Week (Increase)\u003c\/td\u003e\n\u003ctd\u003eNearly \u003cstrong\u003e110%\u003c\/strong\u003e increase\u003c\/td\u003e\n\u003ctd\u003eQ1 2025 vs Q3 2024\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBroad Payer Coverage (Lives)\u003c\/td\u003e\n\u003ctd\u003eOver \u003cstrong\u003e90%\u003c\/strong\u003e of U.S. patients\u003c\/td\u003e\n\u003ctd\u003eQ1 2025\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e High; this is a non-replicable asset built over years of focused effort.\u003c\/p\u003e\n\n\u003cp\u003eThe asset is rare as it represents the culmination of years of development and regulatory engagement required to secure the first and only FDA-approved treatment for Demodex blepharitis. The initial commercial team build-out and subsequent expansion represent a unique, time-intensive investment.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Low; requires successfully navigating the entire drug development and approval process.\u003c\/p\u003e\n\n\u003cp\u003eReplicating this infrastructure requires successfully completing the entire development, clinical trial, and FDA approval process for a novel ophthalmic product, a process that took from the company's founding in 2017 to approval in July \u003cstrong\u003e2023\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High; this infrastructure is actively supporting the XDEMVY launch and pipeline progression.\u003c\/p\u003e\n\n\u003cp\u003eThe organization is actively leveraging this infrastructure, evidenced by:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe planned expansion of the commercial sales force, with an additional \u003cstrong\u003e50\u003c\/strong\u003e sales representatives on track for deployment by the end of Q3 2024, building upon an initial base.\u003c\/li\u003e\n\u003cli\u003eSignificant investment in marketing, with Selling, General and Administrative (SG\u0026amp;A) expenses in Q3 2024 including \u003cstrong\u003e$36.5 million\u003c\/strong\u003e in increased commercial and marketing costs related to the XDEMVY launch.\u003c\/li\u003e\n\u003cli\u003eThe execution of a direct-to-consumer TV campaign, which drove a \u003cstrong\u003e140%\u003c\/strong\u003e increase in average weekly website visits in March 2025 compared to December 2024.\u003c\/li\u003e\n\u003cli\u003eThe Chief Commercial Officer has over \u003cstrong\u003e20\u003c\/strong\u003e years of leadership experience, including over \u003cstrong\u003e10\u003c\/strong\u003e years in the Eye Care space.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained; the regulatory approval and commercial setup for XDEMVY are permanent barriers.\u003c\/p\u003e\n\n\u003cp\u003eThe FDA approval itself creates a permanent barrier to entry for the specific indication. The established relationships with over \u003cstrong\u003e13,000\u003c\/strong\u003e Eye Care Professionals (ECPs) and payer coverage exceeding \u003cstrong\u003e90%\u003c\/strong\u003e of U.S. patients represent entrenched commercial relationships that are difficult and costly for a new entrant to replicate quickly.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eTarsus Pharmaceuticals, Inc. (TARS) - VRIO Analysis: 9. Pipeline Diversification Beyond Core Indication\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue: The pipeline extends beyond eye care into infectious disease (Lyme) and dermatology (Ocular Rosacea), mitigating risk associated with a single indication.\u003c\/strong\u003e\u003c\/p\u003e\n\u003ch\u003e\u003ch\u003ePipeline Assets and Associated Indication Prevalence\u003c\/h\u003e\u003c\/h\u003e\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003eIndication\u003c\/th\u003e\n\u003cth\u003ePrevalence\/Scope\u003c\/th\u003e\n\u003cth\u003eStatus\/Notes\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTP-04\u003c\/td\u003e\n\u003ctd\u003eOcular Rosacea (OR)\u003c\/td\u003e\n\u003ctd\u003eAffects ~15-18 million in the United States\u003c\/td\u003e\n\u003ctd\u003eInvestigational treatment; no FDA-approved therapy exists\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTP-05\u003c\/td\u003e\n\u003ctd\u003eLyme Disease Prophylaxis\u003c\/td\u003e\n\u003ctd\u003eEstimated 300,000 to 400,000 annual cases in the US\u003c\/td\u003e\n\u003ctd\u003eInvestigational oral formulation\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTP-05 (Secondary)\u003c\/td\u003e\n\u003ctd\u003eMalaria Reduction\u003c\/td\u003e\n\u003ctd\u003eApproximately 247 million cases worldwide\u003c\/td\u003e\n\u003ctd\u003ePotential community reduction application\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity: Medium; many biotechs have pipeline diversification, but Tarsus's is focused on a single, proven molecule.\u003c\/strong\u003e\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability: Medium; the strategy is imitable, but the specific assets are not.\u003c\/strong\u003e\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization: High; the company is actively planning the initiation of the TP-04 Phase 2 study in H2 2025.\u003c\/strong\u003e\u003c\/p\u003e\n\u003ch\u003e\u003ch\u003ePipeline Development Milestones\u003c\/h\u003e\u003c\/h\u003e\n\u003cul\u003e\n\u003cli\u003eTP-04 Phase 2 study initiation planned for H2 2025.\u003c\/li\u003e\n\u003cli\u003eTP-04 Phase 2 study results anticipated in 2026.\u003c\/li\u003e\n\u003cli\u003eTP-05 Phase 2 study planned for 2026.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage: Temporary; the advantage is in the potential for future blockbusters, which is inherently uncertain.\u003c\/strong\u003e\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eFinance: draft 13-week cash view by Friday.\u003c\/strong\u003e\u003c\/p\u003e\n\u003ch\u003e\u003ch\u003eLatest Reported Financial Position\u003c\/h\u003e\u003c\/h\u003e\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eAmount (As of Q3 2025)\u003c\/th\u003e\n\u003cth\u003eAmount (As of Q2 2025)\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash, Cash Equivalents, and Marketable Securities\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$401.8 million\u003c\/strong\u003e (As of September 30, 2025)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$381.1 million\u003c\/strong\u003e (As of June 30, 2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Product Sales (Quarterly)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$118.7 million\u003c\/strong\u003e (Q3 2025)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$102.7 million\u003c\/strong\u003e (Q2 2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Loss (Quarterly)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$12.6 million\u003c\/strong\u003e (Q3 2025)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$20.3 million\u003c\/strong\u003e (Q2 2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Loss Per Share (Quarterly)\u003c\/td\u003e\n\u003ctd\u003e$(\u003cstrong\u003e0.30\u003c\/strong\u003e) (Q3 2025)\u003c\/td\u003e\n\u003ctd\u003e$(\u003cstrong\u003e0.48\u003c\/strong\u003e) (Q2 2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45516261195925,"sku":"tars-vrio-analysis","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/tars-vrio-analysis.png?v=1740220275","url":"https:\/\/dcf-model.com\/products\/tars-vrio-analysis","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}